The Phase 2b/3 trial of Anavex's Blarcamesine demonstrates major, statistically significant effects in slowing Alzheimer's Disease. The drug slowed cognitive decline by about 45% over 48 weeks on the ...
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results